Nitrogen Or Chalcogen Bonded Directly To The Hetero Ring Patents (Class 549/449)
  • Patent number: 9051259
    Abstract: A process for producing a perfluorinated functional compound comprises the steps of: A) converting an at least partially hydrogenated alcohol into an at least partially hydrogenated ester compound; and B) reacting said at least partially hydrogenated ester compound with fluorine in the presence of at least one (per)haloolefin comprising at least one carbon-carbon double bond and having at least one fluorine or chlorine atom on either one of the carbon atoms of said double bond, to obtain a perfluorinated ester compound.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: June 9, 2015
    Assignee: SOLVAY SPECIALTY POLYMERS ITALY S.P.A.
    Inventors: Vito Tortelli, Marco Galimberti
  • Publication number: 20150141669
    Abstract: Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
  • Publication number: 20140296240
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Gary Mark COPPOLA, Yuki IWAKI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Gary Michael KSANDER, Muneto MOGI, Robert SUN
  • Publication number: 20140256730
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
    Type: Application
    Filed: January 13, 2014
    Publication date: September 11, 2014
    Applicant: Corsair Pharma, Inc.
    Inventors: Cyrus K. BECKER, Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
  • Publication number: 20140228531
    Abstract: The invention pertains to a method for making a fluoropolymer comprising an aqueous emulsion polymerization of one or more fluorinated monomers wherein said aqueous emulsion polymerization is carried out in the presence of at least one cyclic fluorocompound of the following formula (I): wherein X1, X2, X3, equal or different from each other are independently selected among H, F, and C1-6 (per)fluoroalkyl groups, optionally comprising one or more catenary or non-catenary oxygen atoms; L represents a bond or a divalent group; RF is a divalent fluorinated C1-3 bridging group; Y is a hydrophilic function selected among anionic functionalities, cationic functionalities and non-ionic functionalities.
    Type: Application
    Filed: March 5, 2014
    Publication date: August 14, 2014
    Applicant: SOLVAY SOLEXIS S.p.A.
    Inventors: Giuseppe MARCHIONNI, Vito Tortelli, Ivan Wlassics, Valeri Kapeliouchko
  • Publication number: 20140170506
    Abstract: A nonaqueous solvent for an electricity storage device includes a fluorine-containing cyclic carbonate represented by the following general formula (1) (in general formula (1), R1 is a methyl group or an ethyl group; R2 through R4 are independently fluorine, a methyl group or an ethyl group; and at least one of R2 through R4 is fluorine):
    Type: Application
    Filed: December 16, 2013
    Publication date: June 19, 2014
    Applicant: PANASONIC CORPORATION
    Inventors: Takashi TAKEUCHI, Masaki HASEGAWA, Natsumi GOTO
  • Patent number: 8742142
    Abstract: A process for producing a perfluorinated functional compound is disclosed, which comprises: A. converting an at least partially hydrogenated alcohol into an at least partially hydrogenated fluoroformate compound; B. reacting said at least partially hydrogenated fluoroformate compound with fluorine in the presence of at least one (per)haloolefin comprising at least one carbon-carbon double bond and having at least one fluorine or chlorine atom on either one of the carbon atoms of said double bond, to obtain a perfluorinated fluoroformate compound.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: June 3, 2014
    Assignee: Solvay Specialty Polymers Italy S.p.A.
    Inventors: Vito Tortelli, Marco Galimberti, Guiseppe Marchionni
  • Publication number: 20140114080
    Abstract: A fluorinated monomer has formula (1) wherein R1 is H, F, methyl or trifluoromethyl, R2 and R3 are H or a monovalent hydrocarbon group, R4 to R6 each are a monovalent fluorinated hydrocarbon group, A is a divalent hydrocarbon group, and k1 is 0, 1 or 2. A polymer derived from the fluorinated monomer may be endowed with appropriate water repellency, water slip, acid lability and hydrolysis and is useful as an additive polymer in formulating a resist composition.
    Type: Application
    Filed: December 27, 2013
    Publication date: April 24, 2014
    Applicant: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Masayoshi SAGEHASHI, Koji HASEGAWA, Takeshi SASAMI
  • Patent number: 8703889
    Abstract: A method for making a fluoropolymer comprising an aqueous emulsion polymerization of one or more fluorinated monomers wherein the aqueous emulsion polymerization is carried out in the presence of at least one cyclic fluorocompound of the following formula (I): wherein X1, X2, X3, equal to or different from each other are independently selected among H, F, and C1-6 (per)fluoroalkyl groups, optionally comprising one or more catenary or non-catenary oxygen atoms; L represents a bond or a divalent group; RF is a divalent fluorinated C1-3 bridging group; Y is a hydrophilic function selected among anionic functionalities, cationic functionalities and non-ionic functionalities.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: April 22, 2014
    Assignee: Solvay Solexis S.p.A.
    Inventors: Giuseppe Marchionni, Vito Tortelli, Ivan Wlassics, Valeri Kapeliouchko
  • Publication number: 20130303466
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: November 14, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Alain D. Baron
  • Publication number: 20130245289
    Abstract: A process for producing a perfluorinated functional compound comprises the steps of: A) converting an at least partially hydrogenated alcohol into an at least partially hydrogenated ester compound; and B) reacting said at least partially hydrogenated ester compound with fluorine in the presence of at least one (per)haloolefin comprising at least one carbon-carbon double bond and having at least one fluorine or chlorine atom on either one of the carbon atoms of said double bond, to obtain a perfluorinated ester compound.
    Type: Application
    Filed: November 17, 2011
    Publication date: September 19, 2013
    Applicant: SOLVAY SPECIALTY POLYMERS ITALY S.P.A.
    Inventors: Vito Tortelli, Marco Galimberti
  • Patent number: 8211612
    Abstract: A method for forming a protective film of a fluorine-containing polymer composition excellent in smoothness and adhesiveness on a photoresist. Moreover, there is provided a means for removing the protective film without impairing the underlying photoresist. A polymer coating composition obtainable by dissolving a fluorine-containing polymer compound in a solvent comprising a fluorinated acetal having a specific structure is applied on a photoresist and dried to form a protective film. A fluorinated acetal having the specific structure is suitable as a solvent for being brought into contact with a fluorine-containing polymer film, peeling the film, and forming a photoresist or a lithographic pattern.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: July 3, 2012
    Assignee: Central Glass Company, Limited
    Inventors: Kazuhiko Maeda, Mitsutaka Otani, Haruhiko Komoriya, Takeo Komata, Shinya Akiba
  • Publication number: 20120095243
    Abstract: A process for producing a perfluorinated functional compound is disclosed, which comprises: A. converting an at least partially hydrogenated alcohol into an at least partially hydrogenated fluoroformate compound; B. reacting said at least partially hydrogenated fluoroformate compound with fluorine in the presence of at least one (per)haloolefin comprising at least one carbon-carbon double bond and having at least one fluorine or chlorine atom on either one of the carbon atoms of said double bond, to obtain a perfluorinated fluoroformate compound.
    Type: Application
    Filed: July 6, 2010
    Publication date: April 19, 2012
    Applicant: SOLVAY SOLEXIS S.P.A.
    Inventors: Vito Tortelli, Marco Galimberti, Giuseppe Marchionni
  • Publication number: 20120016140
    Abstract: A device for processing fluids includes a number of fin layers with a number of plates separating the fin layers so that a fluid flow passage is defined through each fin layer. A first fluid inlet is in communication with a first end portion of the fluid flow passage, a first fluid outlet is in communication with a second end portion of the fluid flow passage, a second fluid inlet is in communication with the second end portion of the fluid flow passage and a second fluid outlet in communication with the first end portion of the fluid flow passage. The fluid flowing through the second inlet is subjected to a shearing action by the fin layers so that mass transfer to the fluid flowing through the first inlet occurs. The device may be used for both liquid-liquid processes, such as extraction, or gas-liquid processes, such as adsorption, absorption or desorption and reactions.
    Type: Application
    Filed: July 11, 2011
    Publication date: January 19, 2012
    Inventors: Zhijun JIA, Lawrence Andrew Stryker, Douglas Eugene Decker
  • Publication number: 20110250539
    Abstract: A fluorinated monomer has formula (1) wherein R1 is H, F, methyl or trifluoromethyl, R2 and R3 are H or a monovalent hydrocarbon group, R4 to R6 each are a monovalent fluorinated hydrocarbon group, A is a divalent hydrocarbon group, and k1 is 0, 1 or 2. A polymer derived from the fluorinated monomer may be endowed with appropriate water repellency, water slip, acid lability and hydrolysis and is useful as an additive polymer in formulating a resist composition.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 13, 2011
    Inventors: Masayoshi SAGEHASHI, Koji Hasegawa, Takeshi Sasami
  • Publication number: 20110160415
    Abstract: The invention pertains to a method for making a fluoropolymer comprising an aqueous emulsion polymerization of one or more fluorinated monomers wherein said aqueous emulsion polymerization is carried out in the presence of at least one cyclic fluorocompound of the following formula (I): wherein X1, X2, X3, equal or different from each other are independently selected among H, F, and C1-6 (per)fluoroalkyl groups, optionally comprising one or more catenary or non-catenary oxygen atoms; L represents a bond or a divalent group; RF is a divalent fluorinated C1-3 bridging group; Y is a hydrophilic function selected among anionic functionalities, cationic functionalities and non-ionic functionalities.
    Type: Application
    Filed: July 6, 2009
    Publication date: June 30, 2011
    Applicant: SOLVAY SOLEXIS S.P.A.
    Inventors: Giuseppe Marchionni, Vito Tortelli, Ivan Wlassics, Valeri Kapeliouchko
  • Publication number: 20100113276
    Abstract: The use of N2-phenylamidines of formula (I) as herbicides is described. In this formula (I), R2, R3, R4, R5 and R6 are different radicals and A is a bond or various 1- or polyatomic bridging elements.
    Type: Application
    Filed: March 4, 2008
    Publication date: May 6, 2010
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Birgit Kuhn, Harald Jakobi, Thomas Mueller, Joerg Tiebes, Heinz Kehne, Dirk Schmutzler, Martin Hills, Christopher Rosinger, Klaus Kunz, Mark Wilheim Drewes, Dieter Feucht, Thomas Seitz, Benoit Hartmann, Ralf Dunkel, Joerg Nico Greul, Oliver Guth, Kerstein Ilg, Darren James Mansfeld, Wahed Ahmed Moradi, Peter Dahmen, Ulrike Wachendorf-Neumann, Arnd Voerste, Dale Robert Mitchell, Jean-Pierre Andre Vors, Dale Robert Mitchell, Tom Hough
  • Publication number: 20100104950
    Abstract: Provide are fluorinated cyclic and acyclic carbonate solvent compositions such as various fluorine substituted 1,3-dioxolane-2-one compounds and fluorine substituted 1,3-dioxane-2-one compounds, which are useful as electrolyte solvents for lithium ion batteries.
    Type: Application
    Filed: December 12, 2007
    Publication date: April 29, 2010
    Inventors: William M. Lamanna, Michael J. Bulinski, Michael G. Castello, Jeffrey R. Dahn, Richard M. Flynn, Yadong Wang, Jing Li, Lee Moshurchak
  • Publication number: 20100099894
    Abstract: A method for the synthesis of cyclic acetals comprises reacting at least one carbonyl-function compound selected from aldehydes, ketones, and/or linear acetals, on a polyol in a concentrated aqueous solution exceeding 20 wt % in a reactor containing an acidic catalyst. The carbonyl-function compound is selected so that the cyclic acetal obtained has a water solubility lower than 20000 mg/kg. During the catalytic reaction for the cyclic acetal synthesis, at least one portion of the organic phase containing the cyclic acetal is separated. The acidic catalysis is either homogeneous when using a water-soluble strong acid, or heterogeneous when using a solid acid such as a resin, a zeolite, or any appropriately acidified solid. The extractive reaction method can be used for obtaining high conversions and selectivity.
    Type: Application
    Filed: October 8, 2007
    Publication date: April 22, 2010
    Inventors: Jean-Luc Dubois, Sara Iborra Chornet, Alexandra I. Lucienne Velty, Avelino Corma Canos
  • Publication number: 20090281335
    Abstract: The present invention provides compound(s) selected from the group of compounds represented by structural Formula (I): wherein X, Y and R1 are as described herein, use of such compounds as anaerobic cure accelerators, and compostions including such compounds.
    Type: Application
    Filed: May 7, 2008
    Publication date: November 12, 2009
    Applicant: HENKEL CORPORATION
    Inventors: Andrew Messana, Anthony F. Jacobine, Steven Thomas Nakos, David M. Glaser
  • Publication number: 20090221840
    Abstract: Ethylene carbonate having a highly reduced content of especially diols is provided. A process for purifying ethylene carbonate, including falling crude ethylene carbonate crystals from an upper portion of a tower, melting the crude ethylene carbonate crystal in a bottom portion of the tower, withdrawing a part of the obtained melt from the tower, and flowing the remainder of the obtained melt as a reflux liquid upward for countercurrent contact with the falling crude ethylene carbonate crystals, characterized in that a solid-liquid countercurrent contact region maintained at a constant temperature is formed.
    Type: Application
    Filed: March 16, 2007
    Publication date: September 3, 2009
    Inventors: Masahiko Yamagishi, Toshiyuki Furuya, Hideki Suda
  • Publication number: 20090137660
    Abstract: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group —(CH2)n—CR4R5—(CH2)m— wherein n and m are independently selected integers 0, 1 or 2 and R4 and R5 are independently selected from H, C1-18 alkyl, C1-18 alkoxy, C1-18n hydroxyalkyl, C2-18 alkenyl and C6-18 aryl or aralyalkyl and R3 is the fatty acyl group of an essential polyunsaturated fatty acid.
    Type: Application
    Filed: March 2, 2006
    Publication date: May 28, 2009
    Inventors: Laurence S. Harbige, Michael J. Leach, Paul Barraclough, Anthony P. Dolan
  • Publication number: 20090082311
    Abstract: The present invention provides a novel compound having few side effects such as bradycardia and the like and having superior peripheral blood lymphocyte-decreasing effect.
    Type: Application
    Filed: April 27, 2007
    Publication date: March 26, 2009
    Applicant: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Mitsuharu Nakamura, Maiko Hamada, Kunio Sugahara
  • Patent number: 7442813
    Abstract: The present invention relates to a process conducted in a single reaction vessel for producing a dioxolane nucleoside analogue of formula I or a pharmaceutically acceptable salt thereof; the process comprising the steps of adding a Lewis acid, a silylating agent and a non-silylated purine or pyrimidine base or an analogue thereof to a dioxolane of formula II. The invention also provides a process for producing a dioxolane compound of formula III; by reacting a dioxolane compound of formula IV in a suitable solvent in the presence of DIB and I2, using a suitable source of energy.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: October 28, 2008
    Assignee: Shire Biochem Inc.
    Inventors: Gregory Bydlinski, Qing Yu, Alex Cimpoia
  • Publication number: 20080113924
    Abstract: There are provided a novel compound having irreversible inhibitory activity against neuraminidase, a therapeutic agent and a detection agent for a disease involving neuraminidase. A compound represented by the following formula (I) and a salt thereof, a production method thereof, and an application method thereof, wherein: A1 represents an aryl group optionally having a substituent group or a heteroaryl group optionally having a substituent group; A2 represents —CX2R6 or —CHXR6 wherein X represents —F, —Cl, —Br, or —I; R1 represents a hydrogen atom or an alkyl group optionally having a substituent group; R2, R3, R4, and R5 represent each independently —OC(?O)R6, —OR6, —N(R6)2, —N3, —NHC(?NH)NHR6, —NHCOR6, —OSO3R6, —OPO3(R6)2, F, Cl, Br, or I; and R6 represents each independently a hydrogen atom, an alkyl group optionally having a substituent group, an aryl group optionally having a substituent group, or an optionally substituted heteroaryl group.
    Type: Application
    Filed: December 16, 2005
    Publication date: May 15, 2008
    Applicants: NATIONAL INSTITUE OF ADVANCE INDUSTRIAL SCIENCE AND TECHNOLOGY, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, SUMITOMO BAKELITE CO., LTD.
    Inventors: Shinichiro Nishimura, Hiroshi Hinou, Hirosato Kondo, Kazuhiko Fujiwara
  • Patent number: 7271274
    Abstract: The invention relates to compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, wherein the compounds are of the following Formulas: or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the substituents are defined in the application. The invention further provides methods of treatment of inflammatory disorders by administering the compounds.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: September 18, 2007
    Assignee: AhteroGenics, Inc.
    Inventors: Charles Q. Meng, M. David Weingarten
  • Patent number: 7247737
    Abstract: Perfluoropolyethers obtained by oxidation of perfluorodioxoles of formula (I) wherein Rf=—F, —(O)yCnF2n+1 with y=0, 1 and n=1, 2, 3, 4, 5, and with W=—F, —CnF2n+1, optionally in the presence of tetrafluoroethylene and/or hexafluoropropene, and subsequent reduction of the obtained peroxidic perfluoropolyethers.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: July 24, 2007
    Assignee: Solvay Solexis, S.p.A.
    Inventors: Giuseppe Marchionni, Ugo De Patto
  • Patent number: 6864278
    Abstract: Sordarin derivatives prepared from C-11-hydroxysordarin are antifungal agents useful in the treatment and/or prevention of human and animal fungal infections, as well as in the control of phytopathogenic fungi in crops.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: March 8, 2005
    Assignee: Merck & Co., Inc.
    Inventors: James M. Balkovec, Bruno Tse
  • Patent number: 6696579
    Abstract: An alkylene carbonate such as propylene carbonate is contacted with an alumina or silica solid adsorbent having a surface area of 50-400 m2/g such as basic alumina to remove impurities therefrom and improve color and color stability.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: February 24, 2004
    Assignee: Arco Chemical Technology, L.P.
    Inventor: Andrew P. Kahn
  • Patent number: 6649652
    Abstract: A methods of treating an infection comprises administering a therapeutically effective amount of a compound described by the Formula (I)
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: November 18, 2003
    Assignees: The University of North Carolina at Chapel Hill, Georgia State University Research Foundation, Inc.
    Inventors: David W. Boykin, M. Syed Rahmathullah, Richard R. Tidwell, James E. Hall
  • Patent number: 6576776
    Abstract: Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include efficient methods for the preparation of the 1,3-oxathiolane ring and subsequent condensation of the 1,3-oxathiolane with a pyrimidine or purine base. Using the processes described herein, the compounds can be provided as isolated enantiomers.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: June 10, 2003
    Assignee: Triangle Pharmaceuticals, Inc.
    Inventors: George R. Painter, Dennis C. Liotta, Merrick R. Almond, Darryl G. Cleary, Josè D. Soria, Marcos Sznaidman
  • Patent number: 6562848
    Abstract: This invention relates generally to bis-amino acid sulfonamides containing substituted benzyl amines of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as HIV protease inhibitors, pharmaceutical compositions and diagnostic kits comprising the same, methods of using the same for treating viral infection or as assay standards or reagents, and intermediates and processes for making the same.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: May 13, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventor: Robert F. Kaltenbach
  • Patent number: 6548681
    Abstract: A process for the separation of a polyol or multiple polyols in admixture with other organic compounds, usually those produced with the polyol, is described. The process uses a distillation in a column (11) of a cyclic acetal from an aqueous solution which acetal is formed in a reaction mixture of the polyol and an aldehyde or ketone. The polyols, such as ethylene glycol and propylene glycol, are staple articles of commerce with many uses.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: April 15, 2003
    Assignee: Board of Trustees of Michigan State University
    Inventors: Shubham P. Chopade, Atulkumar D. Dhale, Christopher W. Kiesling, Angela M. Clark, James E. Jackson, Dennis J. Miller
  • Patent number: 6506912
    Abstract: A method of modifying or altering the structured a 1&agr;-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1&agr;-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation in a geometry having an axially orientated 1&agr;-hydroxyl, or by the addition of one or more substituents to the A-ring which interact with other substituents in the molecule or on the A-ring to provide a driving force to the A-ring to adopt a chair conformation which presents the 1&agr;-hydroxyl in the axial orientation.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: January 14, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Rafal R. Sicinski
  • Patent number: 6503940
    Abstract: A methods of treating an infection comprises administering a therapeutically effective amount of a compound described by the Formula (I): wherein: X may be O, S, or NR′ wherein R′ is H or loweralkyl, R1 and R2 may be independently selected from the group consisting of H, loweralkyl, oxyalkyl, alkoxyalkyl, cycloalkyl, aryl, hydroxyalkyl, aminoalkyl, and alkylaminoalkyl; R3 and R4 are each independently selected from the group consisting of H, loweralkyl, halogen, oxyalkyl, oxyaryl, and oxyarylalkyl; R5 is represented by a formula selected from the group consisting of: wherein: X1, X2, and X3 are independently selected from O and S; and R6 and R7 are independently selected from the group consisting of loweralkyl, aryl, alkylaryl, oxyaryl, an ester-containing substituent, and oxyalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: January 7, 2003
    Assignees: The University of North Carolina at Chapel Hill, Georgia State University Research Foundation, Inc.
    Inventors: David W. Boykin, M. Syed Rahmathullah, Richard R. Tidwell, James E. Hall
  • Patent number: 6380257
    Abstract: The present invention relates to new aromatic di-keto derivatives and to their pharmaceutically acceptable salts, esters, ethers and other chemical equivalents. The derivatives are glucose-6-phosphate translocase inhibitors and can be used in the treatment of diabetes mellitus. The present invention further relates to a process for the production of the derivatives, to the use of the derivatives and their pharmaceutically acceptable salts, esters, ethers and other chemical equivalents as pharmaceuticals, in particular to their use in the treatment of diabetes mellitus, and to pharmaceutical compositions comprising the derivatives, pharmaceutically acceptable salts, esters, ethers or other chemical equivalents thereof.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: April 30, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: László Vértesy, Michael Kurz, Erich Paulus
  • Patent number: 6288071
    Abstract: Pesticidally active cyclohexadienyl derivative compounds of the formula I that are esters, oximes or amides are claimed. These compounds may be used as fungicides, acaricides and insecticides in plant protection.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: September 11, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Henry Szczepanski, Martin Zeller, Ottmar Franz Hüter
  • Patent number: 6197817
    Abstract: Disclosed are compounds of the formula: R represents hydrogen or is a C-3 to C-6 cycloalkyl or C-4 to C-10 straight or branched carbon chain alkyl-cycloalkyl or a group —B—D, where B is C-2 to C-10 straight or branched carbon chain alkyl and D is hydroxy or alkyloxy or 2,3-dihydroxypropyl or 2,3-dialkyloxypropyl or 2,2-dialkyl-1,3-dioxolane-5-methyl, where alkyl is C-1 to C-10 straight or branched carbon chain; W represents CH(CH3)CH2—, C(CH3)2CH2—; Z represents hydrogen, —NHCOR2, —NHCONR2R3 or —NHSO2R2 or —NHSO2NR2R3 or —NHCOOR4 wherein R4 is alkyl of from 1 to about 6 carbon atoms, alkoxyalkyl wherein the alkyl groups may be the same or different and contain from 1 to about 6 carbon atoms, alkoxyaryl, cycloalkyl of from 3 to about 8 carbon atoms.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: March 6, 2001
    Assignee: Selectus Pharmaceuticals, Inc.
    Inventors: William L. Matier, Shyam Patil
  • Patent number: 6169188
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: January 2, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • Patent number: 5917059
    Abstract: Cyclic acetals or ketals are prepared by reacting a polyol with the appropriate aldehydes or ketones, with part of the aldehyde or ketone being distilled out during the reaction.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: June 29, 1999
    Assignee: BASF Aktiengesellschaft
    Inventors: Bernd Bruchmann, Karl Haberle, Helmut Gruner, Michael Hirn
  • Patent number: 5834498
    Abstract: The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by the following formula I: ##STR1## wherein wavy line attachments indicate either the alpha (.alpha.) or beta (.beta.) configuration; hatched segments indicate .alpha. configuration, solid triangles are used to indicate .beta. configuration, dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R.sup.1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of --OR.sup.1 and --N(R.sup.1).sub.2, Y is .dbd.O or represents 2 hydrogen radicals. Certain of the compounds represented by Formula I comprise another aspect of the present invention.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: November 10, 1998
    Assignee: Allergan
    Inventor: Robert M. Burk
  • Patent number: 5789394
    Abstract: Nucleotide analogues having the general formula (I) and pharmaceutically acceptable derivatives: ##STR1## wherein n is 0 or an integer; X is O or S, CH.sub.2, CH-halogen, CH--N.sub.3, or C.dbd.CH.sub.2 ;Q and U are independently selected from: O, S, and CH(R.sub.a) wherein R.sub.a is hydrogen, OH, halogen, N.sub.3, NH.sub.2, SH, carboxyl, C.sub.1-6 alkyl or R.sub.a is CH.sub.2 (R.sub.b) wherein R.sub.b is hydrogen, OH, SH, NH.sub.2, C.sub.1-6 alkyl or carboxyl; or both Q and U are CH when Q and U are linked by a double bond;Z is selected from: O, a C.sub.1-6 alkoxy, a C.sub.1-6 thioalkyl, a C.sub.1-6 aminoalkyl, (CH.sub.2).sub.m wherein m is 0 or an integer, and N(R.sub.c).sub.2 wherein both R.sub.c are independently hydrogen or a C.sub.1-6, alkyl; andR2 is a purine or pyrimidine base or an analogue or derivative thereof are disclosed. Members of this series of analogues possess anti-viral activity.
    Type: Grant
    Filed: April 29, 1996
    Date of Patent: August 4, 1998
    Inventors: Nghe Nguyen-Ba, Miguel Quimpere, Laval Chan Chung Kong, William L. Brown, Gervais Dionne
  • Patent number: 5691372
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: November 25, 1997
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Govinda Rao Bhisetti
  • Patent number: 5674894
    Abstract: The current invention discloses novel amidine derivatives with nitric oxide donating property that can inhibit platelet aggregation and promote vasodilation in a single compound.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: October 7, 1997
    Assignee: G.D. Searle & Co.
    Inventors: Mark G. Currie, Foe S. Tjoeng, Mark E. Zupec
  • Patent number: 5674811
    Abstract: A cyanoketone derivatives of the following formula (1) ##STR1## which are characterized by excellent herbicidal activity and effectiveness against a variety of broad leafed weeds, including barnyard grass, green foxtail, velvet leaf, livid amaranth and hairy beggar ticks.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: October 7, 1997
    Assignee: Tokuyama Corporation
    Inventors: Toshio Kitajima, Tadashi Kobutani, Shozo Kato, Masao Yamaguchi, Masahiko Ishizaki, deceased
  • Patent number: 5672718
    Abstract: The present invention relates to novel N-phenylacetamino nitriles of the general formula (I), ##STR1## in which R.sup.1 represents hydrogen, or represents alkyl, alkenyl, cycloalkyl, aryl or heterocyclyl which are in each case optionally substituted, andR.sup.2 represents hydrogen, or represents alkyl which is optionally substituted, orR.sup.1 and R.sup.2, together with the carbon atom to which they are bonded, represent cycloalkyl or heterocyclyl which are in each case optionally substituted,R.sup.3 represents halogen, alkyl or alkoxy,R.sup.4 represents hydrogen, halogen, alkyl, halogenoalkyl or alkoxy,R.sup.5 represents halogen, alkyl or alkoxy, andm represents a number 0, 1, 2 or 3, processes for their preparation and their use for the preparation of agents for controlling pests.
    Type: Grant
    Filed: November 15, 1995
    Date of Patent: September 30, 1997
    Assignee: Bayer Aktiengesellschaft
    Inventors: Reiner Fischer, Gunther Beck
  • Patent number: 5629265
    Abstract: Disclosed herein are cyanoketone derivatives of the following formula (1) ##STR1## such as 1-cyano-1-piperidinocarbonyl-3-[4-(2-chloro-4-trifluoromethylphenoxy)pheno xy]-2-butanone, 1-cyano-1-piperidinocarbonyl-3-[4-(3-chloro-5-trifluoromethyl-2-pyridyloxy )phenoxy]-2-butanone, 1-cyano-1-(N-methyl-N-dichlorophenyl)aminocarbonyl-3-[4-(2-quinoxalyloxy)p henoxy]-2-butanone, 1-cyano-1-(N,N-dibutyl)aminocarbonyl-3-[4-(3-chloro-5-trifluoromethyl-2-py ridyloxy)phenoxy-2-butanone, and the like, which are characterized by excellent herbicidal activity and effectiveness against a variety of gramineous weeds.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: May 13, 1997
    Assignee: Tokuyama Corporation
    Inventors: Masahiko Ishizaki, Seiji Nagata, Junji Takenaka
  • Patent number: 5563168
    Abstract: O-Benzyloxime ethers of the formula I ##STR1## where 5 X is substituted or unsubstituted CH.sub.2, NOalkylY isO, S, NR.sup.5R.sup.1, R.sup.2, R.sup.5 are H, alkylZ.sup.1, Z.sup.2 are H, halogen, methyl, methoxy, cyanoR.sup.3, R.sup.4 are hydrogen, cyano, substituted or unsubstituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkynyl, alkoxy, haloalkoxy, alkylthio, benzylthio, alkylcarbonyl, substituted or unsubstituted phenylcarbonyl, substituted or unsubstituted benzylcarbonyl, alkoxycarbonyl, substituted or unsubstituted phenoxycarbonyl, substituted or unsubstituted benzyloxycarbonyl,N(R.sup.6).sub.2, where R.sup.6 is H, alkyl, substituted or unsubstituted phenyl,--CO--N(R.sup.7).sub.2, where R.sup.
    Type: Grant
    Filed: June 16, 1995
    Date of Patent: October 8, 1996
    Assignee: BASF Aktiengesellschaft
    Inventors: Siegbert Brand, Uwe Kardorff, Reinhard Kirstgen, Bernd Mueller, Klaus Oberdorf, Hubert Sauter, Gisela Lorenz, Eberhard Ammermann, Christoph Kuenast, Albrecht Harreus
  • Patent number: 5498799
    Abstract: An optically active 5-methylenedioxolan-4-one derivative is subjected to Diels-Alder reaction with cyclopentadiene, and the resulting Diels-Alder reaction product is hydrolyzed to convert it into an optically active 2-hydroxynorbornene-2-carboxylic acid, which is then subjected to catalytic hydrogenation to form an optically active 2-hydroxynorbornane-2-carboxylic acid. The hydroxycarboxylic acid is subjected to oxidative decarboxylation to obtain an optically active 2-norbornanone.
    Type: Grant
    Filed: August 19, 1994
    Date of Patent: March 12, 1996
    Assignee: Kuraray Co., Ltd.
    Inventors: Masahiro Torihara, Yoshin Tamai
  • Patent number: 5422373
    Abstract: Diaryl urea compounds having anti-atherosclerosis activity are disclosed. Preferred compounds include the compounds 1-[4-(1,2-dimethoxyethoxy)benzyl-3-(2,4-dimethoxyphenyl)-l-heptylumea and 1-heptyl-3-(2,4-dimethoxyphenyl)-l-[4-(2-methoxyethoxymethoxy)-benzyl]urea .
    Type: Grant
    Filed: March 23, 1993
    Date of Patent: June 6, 1995
    Assignee: Burroughs Wellcome Co.
    Inventor: Karl W. Franzmann